Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Ginkgo Bioworks Holdings Updates FY2025 Sales Guidance from $160.00M-$180.00M to $167.00M-$187.00M vs $202.01M Est

Author: Benzinga Newsdesk | May 06, 2025 05:04pm

Ginkgo previously issued 2025 guidance for Total revenue of $160-$180 million, Cell Engineering revenue of $110-$130 million; and Biosecurity revenue of at least $50 million. Ginkgo updates its previously issued guidance solely to reflect the impact of the previously mentioned $7 million non-cash deferred revenue release in the first quarter to:
- Total revenue of $167-$187 million in 2025;
- Cell engineering revenue of $117-$137 million in 2025; and
- Biosecurity revenue of at least $50 million in 2025.

Posted In: DNA